TY - JOUR
T1 - Analysis of morbidity and clinical implications of laparoscopic para-aortic lymphadenectomy in a continuous series of 98 patients with advanced-stage cervical cancer and negative PET-CT imaging in the para-aortic area
AU - Uzan, Catherine
AU - Souadka, Amine
AU - Gouy, Sebastien
AU - Debaere, Thierry
AU - Duclos, Juliette
AU - Lumbroso, Jean
AU - Haie-Meder, Christine
AU - Morice, Philippe
PY - 2011/7/1
Y1 - 2011/7/1
N2 - Background. Laparoscopic para-aortic lymphadenectomy (PAL) is being used increasingly to stage patients with locally advanced cervical cancer (LACC) and to define radiation field limits before chemoradiation therapy (CRT). This study aimed to define clinical implications, review complications, and determine whether surgical complications delayed the start of CRT. Methods. We retrospectively reviewed a continuous series of patients with LACC, with no positive para-aortic (PA) nodes on positron emission tomography- computed tomography (PET-CT) and who had undergone a primary laparoscopic PAL. Results. From November 2007 to June 2010, 98 patients with LACC underwent pretherapeutic PAL. Two patients did not undergo PAL: extensive carcinomatosis was discovered in one case and a technical problem arose in the other. No perioperative complications occurred. Seven patients had a lymphocyst requiring an imaging-guided (or laparoscopic) puncture. Eight patients (8.4%, which corresponds to the false-negative PET-CT rate) had metastatic disease within PA lymph nodes. In cases of suspicious pelvic nodes on PET-CT, the risk for PA nodal disease was greater (24.0% versus 2.9%). When patients with and without surgical morbidity were compared, the median delay to the start of treatment was not significantly different (15 days; range, 3-49 days versus 18 days; range, 3-42 days). Conclusions. The morbidity of laparoscopic PAL was limited and the completionoftreatment was not delayed when complications occurred. Nevertheless, if PET-CT of the pelvic area is negative, the interest in staging PAL could be discussed because the risk for PA nodal disease is very low.
AB - Background. Laparoscopic para-aortic lymphadenectomy (PAL) is being used increasingly to stage patients with locally advanced cervical cancer (LACC) and to define radiation field limits before chemoradiation therapy (CRT). This study aimed to define clinical implications, review complications, and determine whether surgical complications delayed the start of CRT. Methods. We retrospectively reviewed a continuous series of patients with LACC, with no positive para-aortic (PA) nodes on positron emission tomography- computed tomography (PET-CT) and who had undergone a primary laparoscopic PAL. Results. From November 2007 to June 2010, 98 patients with LACC underwent pretherapeutic PAL. Two patients did not undergo PAL: extensive carcinomatosis was discovered in one case and a technical problem arose in the other. No perioperative complications occurred. Seven patients had a lymphocyst requiring an imaging-guided (or laparoscopic) puncture. Eight patients (8.4%, which corresponds to the false-negative PET-CT rate) had metastatic disease within PA lymph nodes. In cases of suspicious pelvic nodes on PET-CT, the risk for PA nodal disease was greater (24.0% versus 2.9%). When patients with and without surgical morbidity were compared, the median delay to the start of treatment was not significantly different (15 days; range, 3-49 days versus 18 days; range, 3-42 days). Conclusions. The morbidity of laparoscopic PAL was limited and the completionoftreatment was not delayed when complications occurred. Nevertheless, if PET-CT of the pelvic area is negative, the interest in staging PAL could be discussed because the risk for PA nodal disease is very low.
KW - Cervical cancer
KW - Laparoscopy
KW - Lymphocyst
KW - Morbidity
KW - Para-aortic lymphadenectomy
KW - Staging
UR - http://www.scopus.com/inward/record.url?scp=79960885593&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2011-0007
DO - 10.1634/theoncologist.2011-0007
M3 - Article
C2 - 21659610
AN - SCOPUS:79960885593
SN - 1083-7159
VL - 16
SP - 1021
EP - 1027
JO - Oncologist
JF - Oncologist
IS - 7
ER -